Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cross Country Healthcare (CCRN) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Cross Country Healthcare (CCRN) over the last 16 years, with Q3 2025 value amounting to $6000.0.

  • Cross Country Healthcare's Gains from Investment Securities changed 0.0% to $6000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 7246.73%. This contributed to the annual value of $3.0 million for FY2024, which is 3964.11% down from last year.
  • Cross Country Healthcare's Gains from Investment Securities amounted to $6000.0 in Q3 2025, which was down 0.0% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Cross Country Healthcare's Gains from Investment Securities registered a high of $5.0 million during Q1 2022, and its lowest value of -$202000.0 during Q1 2025.
  • Over the past 5 years, Cross Country Healthcare's median Gains from Investment Securities value was $243500.0 (recorded in 2022), while the average stood at $1.2 million.
  • As far as peak fluctuations go, Cross Country Healthcare's Gains from Investment Securities soared by 78695.65% in 2021, and later plummeted by 10746.49% in 2025.
  • Over the past 5 years, Cross Country Healthcare's Gains from Investment Securities (Quarter) stood at $204000.0 in 2021, then grew by 17.16% to $239000.0 in 2022, then crashed by 94.56% to $13000.0 in 2023, then crashed by 53.85% to $6000.0 in 2024, then changed by 0.0% to $6000.0 in 2025.
  • Its last three reported values are $6000.0 in Q3 2025, $2.0 million for Q2 2025, and -$202000.0 during Q1 2025.